Abstract: SA-PO0501
OBERCE Project: The Burden of Obesity in CKD, a Spanish Multicenter Study
Session Information
- CKM: Clinical - Screening, Population Management, Care Disparities, and Patient-Centered Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- García-Carro, Clara, Hospital Clinico San Carlos, Madrid, Community of Madrid, Spain
- Soler, Maria Jose, Hospital Universitari Vall d'Hebron, Barcelona, CT, Spain
Group or Team Name
- On behalf of OBERCE project investigators
Background
Obesity and CKD have increased in parallel and share interconnected pathophysiological mechanisms. However, data regarding the true prevalence of obesity in patients with CKD and its current management remain scarce. The aim of this study was to estimate the prevalence of obesity in a contemporary Spanish CKD cohort, describe the clinical profile, and analyze the use of cardiorenal-metabolic therapies.
Methods
Cross-sectional study including adults with CKD followed in Nephrology clinics from 20 Spanish hospitals between Feb-Aug2025. Patients on dialysis or with kidney transplantation were excluded.
Results
2,036 individuals were included. Median age 71.6 years; median eGFR 38.7 mL/min/1.73 m2, median albuminuria88.5 mg/g creatinine. DM was present in 55%. Obesity prevalence varied according to the diagnostic criterion used: 38.9% BMI >30 kg/m2, 62.3% fulfilled abdominal obesity criteria based on waist circumference, and 87.2% according to waist-to-height ratio (WHtR). When applying the criteria for clinical obesity diagnosis (BMI >30 kg/m2 +1confirmatory anthropometric measure, or 2 abnormal anthropometric measures with BMI≤30 kg/m2), prevalence reached 63.5%. 27.4% of patients with clinical obesity had hidden obesity, defined as normal BMI but 2 abnormal anthropometric measures, translating abnormal visceral adiposity.
Patients with clinical obesity were more frequently women (45.7% vs. 29.8%; p<0.001) and more commonly had hypertension and DM. They received ACEi/ARBs, MRAs, SGLT2i and GLP-1 RA more frequently compared with those without obesity. Only 24.1% of patients with clinical obesity were treated with GLP-1 RA. Women with clinical obesity had worse kidney function (eGFR 36 vs. 40; p=0.012) and were less likely to receive cardiorenometabolic therapies (p<0.05).
Conclusion
In more than 2,000 patients with CKD in a European cohort, obesity affected 63.5% and was more frequent in women; 27% presented obesity despite BMI<30. Only 1 in 4 patients with obesity received GLP-1 RA, and a significant gender gap in access to cardiorenometabolic therapies was observed. There is an urgent need to move beyond BMI alone for obesity diagnosis in CKD and to address inequalities in obesity treatment.
Acknowledgment
This project was conducted under the sponsorship of the Spanish Society of Nephrology and funded by Novo Nordisk
Funding
- Commercial Support – Novo Nordisk